Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There’s a Clear Winner.
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Tesla's Musk Uses Weight-Loss Drugs as Eli Lilly and Novo Nordisk Dominate the Market
Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
US FDA says Lilly’s weight-loss drug shortage is resolved
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...
Lilly’s US weight-loss drug shortage ends, curtailing copycats
Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...
CNBC on MSN11d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision could pave the way for Eli Lilly to gain broader insurance coverage for Zepbound, which, like other ...
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...